ARTICLE | Distillery Therapeutics
Therapeutics: Argonaute RISC catalytic component 2 (AGO2); fragile X mental retardation autosomal homolog 1 (FXR1)
June 4, 2015 7:00 AM UTC
In vitro studies suggest promoting expression of AGO2 and FXR1 could help treat MS. In CNS tissue, oligodendrocytes and brain-infiltrating T cells from the experimental autoimmune encephalomyelitis (E...